Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Up 0.1 %

Shares of BSX Stock opened at $41.03 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 0.51. Boston Scientific has a 1 year low of $34.98 and a 1 year high of $47.49. The firm's fifty day moving average price is $38.31 and its two-hundred day moving average price is $41.24. The firm has a market capitalization of $58.66 billion, a P/E ratio of 70.74, a PEG ratio of 2.22 and a beta of 0.85.

Boston Scientific (NYSE:BSX - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.02. The company had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Boston Scientific had a net margin of 7.16% and a return on equity of 14.58%. Boston Scientific's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.40 EPS. On average, equities analysts predict that Boston Scientific will post 1.76 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BSX. BTIG Research lifted their price target on shares of Boston Scientific from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, July 28th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Thursday, April 21st. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $51.00 to $43.00 and set a "buy" rating on the stock in a research report on Wednesday, June 29th. Truist Financial cut their price objective on shares of Boston Scientific from $51.00 to $45.00 and set a "buy" rating on the stock in a research report on Wednesday, July 20th. Finally, Wolfe Research started coverage on shares of Boston Scientific in a research report on Tuesday, July 5th. They issued an "outperform" rating and a $43.00 price objective on the stock. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $46.55.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the completion of the sale, the executive vice president now owns 132,413 shares of the company's stock, valued at approximately $5,031,694. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the completion of the sale, the executive vice president now owns 132,413 shares of the company's stock, valued at approximately $5,031,694. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nelda J. Connors sold 16,088 shares of the business's stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $41.58, for a total transaction of $668,939.04. Following the completion of the sale, the director now directly owns 4,877 shares of the company's stock, valued at approximately $202,785.66. The disclosure for this sale can be found here. Insiders have sold 59,264 shares of company stock worth $2,382,173 in the last ninety days. Insiders own 0.66% of the company's stock.